爱尔眼科(300015) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥5,196,134,001.26, representing a 3.50% increase compared to ¥5,020,539,960.94 in the same period last year[2]. - Net profit attributable to shareholders for Q1 2024 was ¥899,476,291.54, reflecting a 15.16% increase from ¥781,064,898.92 year-on-year[2]. - Basic earnings per share increased by 15.50% to ¥0.0976 from ¥0.0845 in the same period last year[2]. - The total profit for Q1 2024 was CNY 1,202,607,404.60, an increase from CNY 1,132,980,006.15 in Q1 2023, representing a growth of approximately 6.1%[18]. - The total operating costs for Q1 2024 were CNY 4,021,509,579.51, compared to CNY 3,896,380,425.67 in Q1 2023, reflecting an increase of about 3.2%[17]. Cash Flow - The net cash flow from operating activities decreased by 21.91% to ¥1,290,939,304.47 from ¥1,653,223,002.26 in the previous year[2]. - The cash inflow from operating activities amounted to ¥5,256,300,803.12, an increase of 9.45% compared to ¥4,802,636,185.86 in the previous period[20]. - The cash outflow for investing activities totaled ¥455,322,713.03, significantly lower than ¥1,192,694,050.05 in the previous period, indicating a reduction of 61.86%[21]. - The net cash flow from investing activities was -¥440,953,103.74, an improvement from -¥879,272,407.99 in the previous period[21]. - The cash inflow from financing activities was ¥20,082,246.74, slightly down from ¥21,696,824.07 in the previous period[21]. - The net cash flow from financing activities decreased to -¥305,067,125.92, compared to -¥215,262,680.44 in the previous period[21]. Assets and Liabilities - Total assets at the end of Q1 2024 were ¥30,899,280,579.23, up 2.36% from ¥30,186,619,945.52 at the end of the previous year[2]. - The total liabilities decreased to CNY 9,975,555,946.18 from CNY 10,161,858,405.60, a reduction of approximately 1.8%[16]. - The total equity increased to CNY 20,923,724,633.05 from CNY 20,024,761,539.92, marking an increase of about 4.5%[16]. - The company's retained earnings rose to CNY 9,279,591,326.10 from CNY 8,380,115,034.56, an increase of approximately 10.7%[16]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 338,428[7]. - The largest shareholder, Aier Medical Investment Group, holds 3,202,323,587 shares, representing 34.33% of total shares[7]. - The second-largest shareholder, Chen Bang, holds 15.48% of the shares, amounting to 1,443,791,891 shares[7]. - The company has a diverse shareholder base, including domestic and foreign entities, with varying percentages of ownership[7]. - The top ten shareholders collectively hold a significant portion of the company's shares, with no shareholder among them having a relationship that would classify them as acting in concert[8]. Research and Development - The company reported a 12.18% increase in R&D expenses, totaling ¥74,654,886.82 compared to ¥66,549,935.52 in the previous year[6]. - Research and development expenses for Q1 2024 were CNY 74,654,886.82, up from CNY 66,549,935.52 in Q1 2023, indicating an increase of approximately 12.5%[17]. Other Income and Expenses - Other income surged by 660.70% to ¥85,081,860.24 from ¥11,184,692.01, primarily due to increased government subsidies received by subsidiaries[6]. - The company experienced a 46.37% decline in investment income, which fell to ¥1,823,265.17 from ¥3,399,520.17 year-on-year[6]. - Other comprehensive income after tax for Q1 2024 was CNY -34,939,834.55, compared to CNY 14,330,809.88 in Q1 2023, indicating a significant decline[18]. Inventory and Assets Management - The company reported a decrease in inventory from 899,686,324.79 yuan to 776,094,375.87 yuan, a decline of about 13.7%[13]. - Cash and cash equivalents increased to 6,625,981,574.50 yuan from 6,099,082,253.65 yuan, representing an increase of approximately 8.6%[13]. - Accounts receivable rose to 2,105,478,461.95 yuan from 1,899,196,193.66 yuan, reflecting an increase of about 10.9%[13]. - Total current assets increased to 10,812,490,202.36 yuan from 10,185,995,877.77 yuan, marking a growth of approximately 6.1%[14]. - Non-current assets totaled 20,086,790,376.87 yuan, slightly up from 20,000,624,067.75 yuan, indicating a marginal increase[14].